An estimate of asthma prevalence in Africa: a systematic analysis

Aim To estimate and compare asthma prevalence in Africa in 1990, 2000, and 2010 in order to provide information that will help inform the planning of the public health response to the disease.

Methods We conducted a systematic search of Medline, EMBASE, and Global Health for studies on asthma published between 1990 and 2012. We included cross-sectional population based studies providing numerical estimates on the prevalence of asthma. We calculated weighted mean prevalence and applied an epidemiological model linking age with the prevalence of asthma. The UN population figures for Africa for 1990, 2000, and 2010 were used to estimate the cases of asthma, each for the respective year.

Results Our search returned 790 studies. We retained 45 studies that met our selection criteria. In Africa in 1990, we estimated 34.1 million asthma cases (12.1%; 95% confidence interval [CI] 7.2-16.9) among children <15 years, 64.9 million (11.8%; 95% CI 7.9-15.8) among people aged <45 years, and 74.4 million (11.7%; 95% CI 8.2-15.3) in the total population. In 2000, we estimated 41.3 million cases (12.9%; 95% CI 8.7-17.0) among children <15 years, 82.4 million (12.5%; 95% CI 5.9-19.1) among people aged <45 years, and 94.8 million (12.0%; 95% CI 5.0-18.8) in the total population. This increased to 49.7 million (13.9%; 95% CI 9.6-18.3) among children <15 years, 102.9 million (13.8%; 95% CI 6.2-21.4) among people aged <45 years, and 119.3 million (12.8%; 95% CI 8.2-17.1) in the total population in 2010. There were no significant differences between asthma prevalence in studies which ascertained cases by written and video questionnaires. Crude prevalences of asthma were, however, consistently higher among urban than rural dwellers.

Conclusion Our findings suggest an increasing prevalence of asthma in Africa over the past two decades. Due to the paucity of data, we believe that the true prevalence of asthma may still be under-estimated. There is a need for national governments in Africa to consider the implications of this increasing disease burden and to investigate the relative importance of underlying risk factors such as rising urbanization and population aging in their policy and health planning responses to this challenge.
Chronic respiratory diseases (CRDs) are among the leading causes of death worldwide, with asthma rated the most common chronic disease affecting children (1). Globally, about 300 million people have asthma, and current trends suggest that an additional 100 million people may be living with asthma by 2025 (1,2). The World Health Organization (WHO) estimates about 250,000 deaths from asthma every year, mainly in low- and middle-income countries (LMIC) (3,4). Just like with many other chronic diseases in Africa, the fast rate of urbanization has been linked to the increase in the burden of asthma and other allergic diseases (3,5,6). The prevalence of these conditions may, in theory, have the potential to reach levels higher than those observed in high-income countries (HIC) due to priming effects of parasitic helminthic infections on the immune system, as these infections are common in many African settings (5).

The International Study of Asthma and Allergies (ISAAC) reported that asthma prevalence among children was increasing in Africa and has contributed most to the burden of disease through its effects on quality of life (3). In-patient admissions and purchase of medications account for most of the direct costs on government, while loss of productivity, due to absenteeism from work and school, are responsible for most of the indirect costs (7,8).

Asthma is widely known as a multifactorial respiratory disorder with both genetic and environmental underlying risk factors (3). Exposure to common allergens (including pollen, dust mites, and animal furs) and indoor and outdoor air pollution from various sources (eg, traffic pollution, combustion of fossils and biomass fuels, workplace dust) have all been implicated as triggers of the disease (9). Second hand tobacco smoking is a confirmed risk factor in pediatric patients (5,10). Viral infections, a major cause of upper respiratory tract infections and “common cold,” are also a common risk factor in children (11,12). As noted, helminthic infections are relatively common in Africa and are associated with bronchial hyper-responsiveness and asthma (5,13); this is perhaps due to the presence of related raised immunoglobulin E (IgE) and a prominent Th2 immune response (5,14).

Studies on asthma are few in Africa, with most publications mainly from South African and Nigerian populations (14). One main factor affecting research output is the diagnosis of asthma, which still remains a challenging issue (15,16). The WHO has emphasized that this has limited on-going research efforts globally (4,16). The International Union against Tuberculosis and Lung Diseases (IUATLD) published one of the first diagnostic and survey guidelines for asthma in 1984, but experts subsequently reported concerns about its precision and reliability (17). According to the Global Initiative for Asthma (GINA), detailed history, physical examination and spirometric lung function tests are vital to the diagnosis and management of asthma (10,18). Generally, a reduction in forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF) may be indicative of asthma, with the amount of reduction proportional to the severity of asthma (4). GINA proposed that an increase in FEV1 of >12% and 200 mL in about 15-20 minutes following the inhalation of 200-400 µg of salbutamol or a 20% increase in PEF from baseline can be employed as standardized criteria in diagnosis of asthma (10). This, however, lacks sensitivity, as many asthmatics, especially those on treatment, may not exhibit an increase in FEV1, and PEF when assessed (16,19). Thus, although asthma is characterized by significant reversibility of airway obstruction, an absence of reversibility may not always exclude the presence of asthma (20). The ISAAC established in 1991, remains the largest epidemiological study among children globally (1). ISAAC methodologies and scoring are currently the most widely employed by researchers in Africa (1,4). This involves both video and written questionnaires, as there were reports that video and pictorial representations of asthma symptoms may contribute to improved case recognition in younger children (1). However, this is still a subject of debate among experts (21). The European Community Respiratory Health Survey (ECRHS), which assessed the prevalence of atopy and symptoms of airway disease among older age groups in Western Europe, has been widely implemented and has reported significant geographic variations in the prevalence of asthma and atopy (9). Despite these revised guidelines, both ISAAC and ECRHS research groups have reported challenges in achieving high sensitivity and specificity in case ascertainment with the symptom “wheeze at rest in the last 12 months” (also regarded as current wheeze, or active wheeze), yielding the highest sensitivity and specificity (1).

In Africa, problems including those arising from the over-utilization of health services, lack of trained staff and diagnostic apparatus, and non-availability and unaffordability of inhaled medications have hindered efforts to improve the management of asthma (22,23). The lack of organized health promotion programs, such as effective control strategies for environmental triggers, air pollutants, and occupational dusts have also contributed to the growing burden (24). The WHO has reported that the levels of asthma control and health responses in the continent have been
below recommended standards, and that these have con-
tributed to the size of the disease burden (3,4). In addition,
although many African countries have national guidelines
for the management of asthma and other CRDs, these
guidelines have not been implemented in most rural areas
(25,26). Economic analyses in many African settings have
shown that direct costs from asthma are usually greater
than the indirect costs. However, indirect costs represent a
relatively higher proportion of total costs among pediatric
than adult patients (8). Moreover, the wider economic bur-
den on individuals, families, employers, and society, due to
loss of future potential source of livelihood, has also been
devastating in many resource-poor settings (22). It is be-
lieved that many children with asthma in Africa may fail to
achieve their full potential if proper management and con-
trol measures are not put in place (1). It has been suggest-
ed that education of health care providers and the public is a vital element of the response to the challenge posed
by asthma in Africa (4,27).

By 2015, it is expected that world’s urban population will
increase from 45% to 59%, with over half of this occurring
in Africa (8). It is also expected that the prevalence of asth-
ma and many chronic diseases in Africa will increase due to
this growing population size and from effects of accompa-
nying urbanization and adoption of western lifestyles (28).
In light of this and of the low research output and poor
availability of health services data on the burden of asth-
ma in Africa, it is important to analyze the available data
through a systematic review of the literature in order to
attempt to quantify the burden, guide health priority set-
tings, and inform the formulation of an appropriate health
policy response.

METHODS

Search strategy and selection criteria

We conducted a systematic search of Medline, EMBASE,
and Global Health. After an initial scoping exercise to
identify Medical Subject Headings ( MeSH) and keywords,
we developed a final search strategy. We further hand-
searched reference lists of retained publications for more
relevant studies. African countries were included as con-
tained in the World Bank list of economies from July 2012
(29) (Table 1).

We retained cross-sectional population-based studies on
asthma conducted primarily on African population groups.
The date of publication was set from 1990 to June 2013.
We included studies providing numerical estimates on the
prevalence of asthma, including non-English publications.
We excluded studies that were mainly reviews, hospital-
based (without a denominator population estimate), with-
out numerical estimates, and conducted on non-human
subjects.

Studies were further checked for clear diagnostic criteria
and survey methods. As noted above, asthma has been
described in various ways by many researchers, we there-
fore allowed for these variations in our analysis (Table 2 and
Supplementary Table 1). However, most survey methods
were mainly based on written or video questionnaires, as
proposed by the ISAAC study group (Table 3 and Supple-
mentary Table 1).

Data extraction and analysis

Relevant data were extracted from retained studies and
saved in Microsoft Excel file-format. All data were double

| TABLE 1. Search terms used in the study |
|-----------------------------------------|
| 1 africa/ or exp africa, northern/ or exp algeria/ or exp egypt/ or exp libya/ or exp morocco/ or exp tunisia/ or exp “africa south of the sahara”/ or exp africa, central/ or exp cameroon/ or exp central african republic/ or exp Chad/ or exp congo/ or exp “democratic republic of the congo”/ or exp equatorial guinea/ or exp gabon/ or exp africa, eastern/ or exp burundi/ or exp djibouti/ or exp eritrea/ or exp ethiopia/ or exp kenya/ or exp rwanda/ or exp somalia/ or exp sudan/ or exp tanzania/ or exp uganda/ or exp africa, southern/ or exp angola/ or exp botswana/ or exp lesotho/ or exp malawi/ or exp mozambique/ or exp nemibia/ or exp south africa/ or exp swaziland/ or exp zambia/ or exp zimbabwe/ or exp “africa, western” or exp benin/ or exp burkina faso/ or exp cape verde/ or exp cote d’ivoire/ or exp gambia/ or exp ghana/ or exp guinea/ or exp guinea-bissau/ or exp liberia/ or exp malawi/ or exp mauritania/ or exp niger/ or exp senegal/ or exp sierra leone/ or exp togo |
| 2 exp vital statistics/ or exp incidence/ |
| 3 (incidence* or prevalence* or morbidity or mortality).tw. |
| 4 (disease adj3 burden).tw. |
| 5 exp “cost of illness” |
| 6 exp quality-adjusted life years/ |
| 7 QALY.tw. |
| 8 Disability adjusted life years.mp. |
| 9 (initial adj2 burden).tw. |
| 10 exp risk factors/ |
| 11 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 |
| 12 exp asthma/ or exp asthma, aspirin-induced/ or exp asthma, exercise-induced/ or exp asthma, occupational/ or exp status asthmaticus/ |
| 13 1 and 11 and 12 |
extracted and sorted by country, study period, age, and their respective case number, sample size, and prevalence estimate. Extracts were grouped into data from written questionnaires or video questionnaires, both including data based on asthma diagnosis, and/or its symptoms (wheeze at rest, wheeze on exercise, nocturnal wheeze, nocturnal cough, or severe wheeze). For studies conducted on the same study site, population or cohort, the first chronologically published study was selected, with all additional data from other studies added to that of the selected paper.

For our analysis, weighted means of asthma symptoms were calculated (pooled from reported crude prevalences in individual studies) and expressed in percentages. Asthma prevalence estimates based on “current wheeze” (wheeze at rest-12 months) have high sensitivities and specificities; we therefore applied extracted values from this in our modeling. Mean age and prevalence were plotted on bubble graphs, and the fitted curve explaining the largest proportion of variance (best fit) was applied. The equation generated determined the prevalence of asthma in Africa at midpoints of the United Nation population 5-year age-groups (for Africa) for the years 1990, 2000, and 2010.

RESULTS

Systematic review

Our main search returned 790 studies; Medline (n = 246), EMBASE (n = 370), and Global Health (n = 174). After screening the titles for relevance (ie, asthma studies conducted primarily in an African population setting) and excluding duplicates, 147 studies were retained. 85 abstracts satisfied our selection criteria (ie, population-based studies providing numerical prevalence estimates of asthma). Applying the quality criteria (ie, studies with clear diagnostic criteria and survey methods), 43 studies were excluded. On hand searching reference lists of selected studies, further 3 studies were included, giving a total of 45 studies retained for the review (Figure 1).

Study characteristics

The 45 retained studies (12, 20, 31-73) covered most parts of Africa. South Africa (11 studies) and Nigeria (8 studies) had the highest publication outputs. Ethiopia and Kenya closely followed with 6 and 5 studies respectively, while Algeria, Morocco, and Tunisia in North Africa had 4 studies each. 14 studies were based on ISAAC guidelines and 31 non-ISAAC.

| Terms | Definition |
|-------|------------|
| Wheeze | A high pitched whistling sound originating from obstructed airways (1). “Wheeze at rest-12 months” refers to the prevalence of wheeze in a person in the last 12 mo. |
| Asthma | A chronic airway disease characterized by wheezing (a high pitched whistling sound originating from obstructed airways). Patient usually presents with chronic airways inflammation, bronchial hyper-responsiveness and reversible airflow obstruction, resulting in the recurrent attacks of wheeze, chest tightness, breathlessness, and occasionally cough and sputum production, all of varying severity and frequency from person to person (1,3,24,87). Asthma ever refers to cumulative prevalence of asthma in a person. |
| Asthma exacerbation | Also known as acute asthma. A sudden progressive episodes of shortness of breath, usually characterized by chest tightness, wheezing, cough, or sputum production (87) |
| Moderate asthma exacerbation | An event that, when recognized, should result in a temporary change in treatment, in an effort to prevent the exacerbation from being severe (24) |
| Severe asthma exacerbation | Events that require urgent action on the part of the patient and physician to prevent a serious outcome, such as hospitalization or death (24) |
| Severe asthma | Uncontrolled asthma which can result in risk of frequent severe exacerbations (or death), and/or adverse reactions to medications, and/or chronic morbidity, including impaired lung function or reduced lung growth in children (24) |
| Asthma control | Extent to which the various manifestation of asthma are reduced or removed by treatment (3,24) |
| Asthma diagnosis | GINA proposed a holistic approach involving detailed history, physical examination and spirometry. An increase in FEV1 of ≥12% and ≥200ml after a bronchodilator is indicative of reversible airflow limitation, which is consistent with asthma. Peak expiratory flow (PEF) with an improvement of 60l/min (or ≥20% of the pre-bronchodilator PEF) after a bronchodilator, or a diurnal variation in PEF of more than 20% (with twice daily readings more than 10%) may also be indicative of asthma. Other non-specific diagnostic tests include methacholine or histamine test, inhaled mannitol or exercise challenge, skin prick test and measurement of serum IgE (10,18) |

*Abbreviations: FEV1 – forced expiratory volume in one second; GINA – Global Initiative for Asthma; IgE – immunoglobulin E; PEF – peak expiratory flow.

www.cmj.hr
guidelines, while 39 studies employed written questionnaires and 6 used video questionnaires (Table 3).

Most studies were conducted mainly on pediatric subjects, mostly defined as less than 15 years of age. For the age
determination of subjects from most studies, birth certificates were usually employed, and in the absence of valid age-verification documents, historical landmarks were employed.

Many studies were conducted within one year (23 studies), sample sizes were mostly less than 1000 (mean 3243; median 2067), and study settings were predominantly mixed (urban and rural) (36 studies) (Table 3).

**Prevalence estimates**

We observed that the prevalence of asthma in some parts of Africa was comparable with that reported from surveys in high-income settings. From studies based on written questionnaires, “asthma ever” (cumulative prevalence of asthma) was highest in South Africa (53%, 5-12 years) in 1997 (20), followed by Egypt (26.5%, 11-15 years) in 2005 (52), Nigeria (18.4%, 15-35 years) in 1995 (45), and Ethiopia (16.3%, >20 years) in 1997 (73). The lowest prevalence was recorded in Gambia (1.9%, >15 years) in 1997 (69). “Current wheeze” (wheeze at rest-12-months) was consistently high in South Africa, 26.8% (13-14 years) in 1994, 23.9% (5-12 years) in 1998, and 20.3% (13-14 years) in 2003 (20,31,62). From studies based on video questionnaires, “current wheeze” was highest in Morocco (12.9%, 6-7 years) in 2003 (31) and Tanzania (12.3%, 9-10 years) in 2008 (35), with South Africa recording the lowest prevalence (6.5%, 6-7 years) in 1995 and 2000, respectively (31,62); there was no reported prevalence of “asthma ever” from studies based on video questionnaires. However, from all studies, the pooled crude prevalences (weighted means) for “current wheeze” was 13.2% (male 10.8%, female 13.1%, mean age 18.4 years), and “asthma ever” was 6.6% (male 6.7%, female 6.3%, mean age 22.9 years) (Table 4). We observed that the pooled crude prevalences were consistently higher among urban dwellers than rural dwellers. “Current wheeze” was 9.6% (male 12.1%, female 7.0%, mean age 19.6 years) in urban settings and 7.0% (male 5.5%, female 3.8%, mean age 17.5 years) in rural settings. “Asthma ever” prevalence was 5.9% (male 5.6%, female 3.9%, mean age 22.9 years) and 5.1% (male 4.2%, female 3.1%, mean age 17.5 years) in urban and rural dwellers, respectively (Table 5).

Our modeling revealed an increasing prevalence of asthma in Africa. We reported 34.1 million asthma cases (12.1%; 95% confidence interval [CI] 7.2-16.9) among children <15 years, 64.9 million asthma cases (11.8%; 95% CI 7.9-15.8) among people aged <45 years, and

---

**Table 3. Asthma study distribution**

| Country: | Number of studies |
|---------|------------------|
| Algeria (32,36,37,44) | 4 |
| Burkina Faso (55,56) | 2 |
| Cameroon (31) | 1 |
| Cape Verde (72) | 1 |
| Congo Brazzaville (31) | 1 |
| Cote d’Ivoire (31,47,63) | 3 |
| DR Congo (31,61) | 2 |
| Egypt (52) | 1 |
| Ethiopia (12,31,32,53,71,73) | 6 |
| Gabon (31) | 1 |
| Gambia (69) | 1 |
| Ghana (41) | 1 |
| Guinea (31) | 1 |
| Kenya (31,39,40,59,68) | 5 |
| Madagascar (66) | 1 |
| Morocco (32,34,44,48) | 4 |
| Mozambique (49) | 1 |
| Nigeria (31,33,38,45,50,51,58) | 8 |
| Rwanda (57) | 1 |
| South Africa (20,31,32,42,43,54,60,62,65,67,70) | 11 |
| Sudan (31,32) | 2 |
| Tanzania (35) | 1 |
| Togo (31) | 1 |
| Tunisia (32,44,46,64) | 4 |

| Duration of study: | Number of studies |
|-------------------|------------------|
| <1 y | 23 |
| 1-3 y | 16 |
| >3 y | 6 |

| Sample size: | Number of studies |
|-------------|------------------|
| <1000 | 18 |
| 1001-3000 | 15 |
| >3000 | 12 |

| Study setting: | Number of studies |
|----------------|------------------|
| rural | 3 |
| urban | 6 |
| mixed | 30 |
| occupational | 8 |

| Study type: | Number of studies |
|-------------|------------------|
| based on ISAAC guidelines* | 14 |
| non-ISAAC guidelines | 31 |
| written questionnaire | 39 |
| video questionnaire | 6 |

*ISAAC – The International Study of Asthma and Allergies.
74.4 million cases (11.7%; 95% CI 8.2-15.3) in the total population in 1990. This increased to 41.3 million (12.9%; 95% CI 8.7-17.0) among children <15 years, 82.4 million (12.5%; 95% CI 5.9-19.1) among people aged <45 years, and 94.8 million (12.0%; 95% CI 5.0-18.8) in the total population in 2000. In 2010, we estimated a total of 49.7 million asthma cases (13.9%; 95% CI 9.6-18.3) among children <15 years, 102.9 million (13.8%; 95% CI 6.2-21.4) among people aged <45 years, and 119.3 million cases (12.8%; 95% CI 8.2-17.1) in the total population. We could not model the asthma prevalences separately for men and women due to very limited data (Figure 2 and Table 6).

**DISCUSSION**

This study, to our knowledge, provides the first systematic, data-derived and continent-wide estimates of asthma prevalence in Africa. Our modeling was based on published epidemiological data on "current wheeze" prevalence, which has relatively higher sensitivity and specificity (1,17, 30), and also shows a significant association between age and asthma prevalence (74).

From the 2010 Institute for Health Metrics and Evaluation (IHME) global burden of disease estimates, chronic respiratory diseases overall burden has been decreasing globally
and was responsible for about 4.7% of global disability adjusted life years (DALYs) in 2010, with asthma accounting for about one-fifth of this (75). However, the IHME reported that DALYs from asthma increased by 4.6% (from 21.5 to 22.5 million) between 1990 and 2010, while deaths decreased by 9.1% (from 0.38 to 0.34 million) over the same period globally (75,76). Concerns have been raised about the application of non-user friendly analytical methods, heavy statistical modeling, and difficulties in assessing the design methodologies and metrics used (77,78). In Africa however, the ISAAC study group, which mainly conducted epidemiological studies on asthma, reported increasing prevalences of asthma across many study settings (31). For example, the prevalence of "current wheeze" (wheeze at rest-12 months) among children aged 13-14 years old in South Africa increased from 16.1% to 20.3% between 1995 and 2002; Nigeria (West Africa) recorded an increase from 10.9% to 13.0%, Ethiopia (Horn of Africa) reported an increase from 6.2% to 9.1%, and Kenya (East Africa) an increase from 13.9% to 18.0% (31,32). Our pooled crude preval-

### TABLE 4. Weighted mean prevalence (pooled crude prevalences) of asthma symptoms from all studies

| Study type       | Asthma indices | Overall study characteristics | All | Male | Female |
|------------------|----------------|------------------------------|-----|------|--------|
|                  |                | study period               | mean age | data points | weighted mean | data points | weighted mean | data points | weighted mean |
| Written questionnaire |                | Asthma (ever)               | 1993-2008 | 22.9 | 50 | 6.6 (4.7-8.6) | 6 | 6.7 (2.3-11.3) | 6 | 6.3 (2.3-10.1) |
|                  |                | Wheeze at rest (12 mo)      | 1993-2010 | 18.4 | 46 | 13.2 (11.6-14.9) | 7 | 10.8 (5.9-15.8) | 7 | 13.1 (7.6-18.4) |
|                  |                | Wheeze at rest (ever)       | 1993-2010 | 14.7 | 12 | 17.7 (10.7-24.6) | 2 | 9.1 (8.8-9.4) | 2 | 6.2 (4.8-7.5) |
|                  |                | Wheeze after exercise (12 mo) | 1995-2003 | 12.3 | 6 | 23.8 (15.9-31.7) | 3 | 14.7 (4.4-33.8) | 3 | 24.6 (11.0-38.2) |
|                  |                | Wheeze after exercise (ever) | 1993-2010 | 12.0 | 11 | 8.9 (5.1-12.8) | 1 | 6.5 | 1 | 6.5 |
|                  |                | Nocturnal wheeze (12 mo)    | 1995-2005 | 15.4 | 6 | 4.9 (2.4-7.4) | 1 | 9.1 | 1 | 10.0 |
|                  |                | Nocturnal wheeze (ever)     | - | - | - | - | - | - | - |
|                  |                | Nocturnal cough (12 mo)     | 1995-2005 | 14.1 | 7 | 24.2 (18.3-30.0) | 3 | 24.5 (11.5-37.4) | 3 | 28.1 (13.2-43.2) |
|                  |                | Severe wheeze (12 mo)       | 1993-2003 | 13.1 | 25 | 4.7 (3.7-5.6) | 4 | 6.0 (4.6-7.4) | 4 | 3.0 (0.8-5.2) |
|                  |                | Severe wheeze (ever)        | 1993-2005 | 12.2 | 2 | 8.8 (5.9-11.6) | 1 | 7.2 | 1 | 5.2 |
|                  |                | Wheeze at rest (12 mo)      | 1995-2008 | 13.0 | 9 | 9.7 (8.9-10.5) | 1 | 11.7 | 1 | 13.0 |
|                  |                | Wheeze at rest (ever)       | 1995-2008 | 13.1 | 8 | 13.2 (12.4-14.0) | 1 | 16 | 1 | 18.2 |
|                  |                | Wheeze after exercise (12 mo) | 1995-2008 | 12.9 | 8 | 15.5 (14.7-16.3) | 1 | 19.1 | 1 | 11.5 |
|                  |                | Wheeze after exercise (ever) | 1995-2008 | 13.0 | 7 | 20.4 (16.9-23.8) | 1 | 28.7 | 1 | 15.4 |
|                  |                | Nocturnal wheeze (12 mo)    | 1995-2008 | 13.0 | 8 | 5.6 (4.8-6.4) | 1 | 9.6 | 1 | 5.1 |
|                  |                | Nocturnal wheeze (ever)     | 1995-2008 | 13.0 | 8 | 8.1 (7.3-8.9) | 1 | 14.9 | 1 | 19.2 |
|                  |                | Nocturnal cough (12 mo)     | 1995-2008 | 12.9 | 8 | 17.7 (16.8-18.5) | 1 | 22.3 | 1 | 20.5 |
|                  |                | Nocturnal cough (ever)      | 1995-2008 | 13.0 | 7 | 24.6 (20.5-28.7) | 1 | 31.9 | 1 | 34.6 |
|                  |                | Severe wheeze (12 mo)       | 1995-2008 | 13.0 | 9 | 6.8 (6.1-7.6) | 1 | 5.3 | 1 | 3.9 |
|                  |                | Severe wheeze (ever)        | 1995-2008 | 13.1 | 8 | 9.6 (8.7-10.3) | 1 | 12.8 | 1 | 13.0 |

### TABLE 5. Rural and urban differences in asthma prevalences

| Asthma indices | Study characteristics | All | Male | Female |
|----------------|----------------------|-----|------|--------|
|                | Study setting | study period | mean age | data points | weighted mean | data points | weighted mean | data points | weighted mean |
| Asthma (ever)  | Rural       | 1993-2008 | 17.5 | 6 | 5.1 (7.2-9.4) | 2 | 4.2 (2.1-6.3) | 2 | 3.1 (0.8-6.2) |
|                | Urban       | 1993-2010 | 22.9 | 7 | 5.9 (2.9-7.9) | 1 | 5.6 | 1 | 3.9 |
| Wheeze at rest (12 mo) | Rural         | 1993-2008 | 17.5 | 6 | 7.0 (2.5-11.5) | 2 | 5.5 (1.4-12.4) | 2 | 3.8 (1.5-12.9) |
|                | Urban       | 1993-2005 | 19.6 | 7 | 9.6 (3.9-15.2) | 1 | 12.1 | 1 | 7 |
DISEASES IN LOW AND MIDDLE INCOME COUNTRIES

Croat Med J. 2013;54:519-31

...ences (weighted means) also reflect this increase; we reported a prevalence of current wheeze (wheeze at rest-12-months) of 13.2% for both written and video questionnaires respectively. Furthermore, in keeping with findings from many studies, our pooled crude prevalences were consistently higher in urban than rural settings, suggesting the effects of increasing urbanization on asthma prevalence in Africa (68,69,71).

From our modeling, we estimated a prevalence of 11.7% for asthma, totaling over 74 million people in 1990, and our 2010 prevalence was 12.8%, about 120 million people. Public health experts have reported that increasing tobacco smoking without appropriate legislation and implementation of relevant health promotional measures in many LMIC, especially in Africa, may also be responsible for the increase in asthma and other chronic respiratory diseases’ burden in the region (2,75,79). In addition, the Global Burden of Asthma Report (GBAR) reported an increasing trend of asthma globally (4). GBAR estimated over 235 million asthma cases worldwide, and about 50 million people living with asthma in Africa in 2004, with the highest prevalence (8.1%) recorded in South Africa (4). The authors argue that this increasing trend is expected due to rise in atopic sensitizations, allergic conditions, and changing patterns of environmental triggers (associated with environmental smoking exposure in children, population growth, and urbanization) in Africa over the last two decades (4). These factors may therefore be indicative of our reported high estimates.

While we aimed to provide an improved prevalence estimate of asthma in Africa by carefully selecting high quality studies and applying simple analytical tools, there are however factors that could have affected our analysis. We thus entertain some degrees of uncertainties beyond the statistical confidence intervals generated, as variations in population settings, diagnostic criteria, sampling strategies, and effects of other health determinants (beyond age of patients) are factors that need be considered. First, the variation in diagnostic criteria was observed across many study settings, with criteria based on asthma symptoms and ISAAC scores frequently used. This could have reflected in our reported high estimates of asthma in Africa, as there is evidence suggesting the ISAAC studies could have over-estimated the prevalence of asthma in Africa, as most study centers were mainly urban (1); and with ISAAC studies conducted mainly in the age range 13-14 years, it may still not be representative of all age-groups and the overall population (1,15). Second, while many studies were cross-

| Age range(years) | 1990 estimates (000) | 2000 estimates (000) | 2010 estimates (000) |
|------------------|----------------------|----------------------|----------------------|
| 0-4              | 13405.19             | 15750.21             | 18946.71             |
| 5-9              | 11202.33             | 13526.59             | 16412.34             |
| 10-14            | 9461.50              | 12041.26             | 14306.87             |
| 15-19            | 7889.99              | 10494.98             | 12758.85             |
| 20-24            | 6497.60              | 8806.244             | 11373.60             |
| 25-29            | 5391.37              | 7149.79              | 9722.56              |
| 30-34            | 4457.30              | 5804.15              | 7946.30              |
| 35-39            | 3648.13              | 4823.34              | 6315.71              |
| 40-44            | 2977.33              | 3996.62              | 5075.31              |
| 45-49            | 2409.99              | 3260.32              | 4208.92              |
| 50-54            | 2009.40              | 2627.89              | 3490.57              |
| 55-59            | 1637.07              | 2064.60              | 2801.72              |
| 60-64            | 1282.71              | 1638.11              | 2172.14              |
| 65-69            | 919.99               | 1226.50              | 1581.25              |
| 70+ years        | 1162.36              | 1593.05              | 2201.80              |
| Asthma cases (<15 y) | 34069.02         | 41318.06             | 49665.92             |
| Estimated prevalence (<15 y) | 0.121 (95%CI: 0.072-0.169) | 0.129 (95%CI: 0.088-0.170) | 0.139 (95%CI: 0.096-0.183) |
| Asthma cases (<45 y) | 64930.74         | 82395.18             | 102858.20             |
| Estimated prevalence (<45 y) | 0.118 (0.079-0.158)* | 0.125 (0.099-0.191) | 0.138 (0.062-0.210) |
| Asthma cases (all) | 74352.26         | 94805.65             | 119314.60             |
| Estimated prevalence (all) | 0.117 (0.082-0.153) | 0.119 (0.050-0.188) | 0.128 (0.082-0.171) |

*CI – confidence interval.
sectional population-based, we also included studies conducted in occupational settings; this is in view of reports revealing that occupational asthma contributes significantly to the global burden of chronic respiratory diseases (73,80), and as these studies reported high prevalences, we understand this could have increased our estimates, too. Third, despite included studies spreading across most parts of Africa (24 countries in total), there are still many countries in Africa that are not included in the review; this reflects data gaps in the continent, and thus the generalizability of our estimates for Africa may need to be carefully examined. In addition, our overall sample size of 187,904 (from all studies) may not be a representative sample of the general African population as there were more younger age groups. Finally, data on age- and sex-specific prevalence, including corresponding data on urban-rural settings, which are vital comparative indices in any study, were not always provided across many studies.

**Management of asthma and public health challenges in Africa**

It is important to note that chronic respiratory disease burden, including asthma has continued to increase in Africa due to lack of appropriate response from the governments of many African countries (81,82). The national emphasis on asthma and relevant health messages have been sub-optimal, leading in sequence, to poor awareness of the burden, low prioritization, inadequate staffing and resources, and very low budget allocation. In fact, budget allocation in many African countries mainly targets infectious diseases; funds have been greatly biased toward HIV/AIDS, malaria, and tuberculosis, as these are the main government priorities (28,83). The GBAR authors reported that poor government allocation of funds for asthma remained an important factor responsible for limited access to asthma medications, emergency health care, and other related health services in Africa (4). In addition, with tobacco companies still supporting many African governments, tobacco products’ sales have increased, and government funds have remained unavailable for research on asthma, as researches aimed at improving management of asthma may be against tobacco sales and consumption (22,69). This has greatly resulted in increased smoking (without a counter legislation) and a growing burden of asthma, especially among children in Africa over the last two decades (5,10). For example, Mackay et al reported that a comprehensive smoke-free legislation was important to achieving reduction in the asthma incidence among people without occupational exposure to environmental tobacco smoke; a reduction of 18.2% per year was observed in hospital admissions in Scotland among children <15 years in 2009 compared to a mean increase of admission of 5.2% per year before implementation of the legislation in 2006 (84).

The diagnosis and treatment of asthma still remains a major challenge in Africa (16). Distinguishing asthma from other obstructive airway diseases has posed a clinical challenge to clinicians (3,5). Epidemiological data have shown that while asthma presents in episodes, usually among non-smokers and onsets before 40 years, chronic obstructive pulmonary disease (COPD) is associated with smokers, people aged 40 years and above, with symptoms being persistent and progressive (1). In practice, asthmatics who smoke may have non-reversible airflow limitation, and some COPD patients may be non-smokers having reversible airflow limitation (85). In addition, many African countries have no standard protocols for the diagnosis and management of asthma (22); where these are available, guidelines are rarely implemented, and for the few implemented guidelines, treatment often does not reach the rural population that is mostly affected (26). In fact, inaccessibility of health care services in many rural and resource-poor African settings often gives traditional healers undue significance in the management of many chronic diseases (22). The non-availability and unaffordability of inhaled steroids, and the relative non-adherence to these medications (when available) have also had large negative impact on the response to asthma in Africa. Studies have shown that about 50% of people adhere to prescribed medications (26,86), with reasons for non-adherence including side-effects, dosing frequencies, and lack of patient education on their illness, need for treatment, and how to take medications (87). There are also inherent socio-cultural misconceptions and individual values that need to be understood and addressed toward improving the acceptance and use of asthma medications (88), with continual public awareness and education being advocated, especially among parents of children with asthma (5,88).

Asthma is an important and increasing public health problem in Africa which receives inadequate priority and attention. With increasing urbanization, population aging, and adoption of western lifestyles in many African settings, these trends are set to continue in the near future. There is a need to identify and prioritize feasible strategies that can be adopted to promote the implementation of effective interventions that will address this increasing burden in Africa. There is also a need for African national governments to also consider effects of associated
risk factors in public health policy planning on this topic with a focus on reducing environmental triggers, placing restrictions on tobacco adverts, and appropriately educating health care personnel and the public on the management of the disease and the preventive measures.

Funding None.

Ethical approval Not required.

Authorship declaration All co-authors designed and conducted the study and contributed to the writing of the paper.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1 IUATLD. The Global Asthma Report 2011. Paris: The International Union Against Tuberculosis and Lung Disease; 2011.
2 Anandan C, Nurmatov U, van Schaeyck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy. 2010;65:152-67. Medline:19912154 doi:10.1111/j.1398-9995.2009.02244.x
3 Bousquet J, Mantzouranis E, Cruz AA, Air-Khaled N, Baena-Cagnani CE, Bleeker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126:926-38. Medline:20926125 doi:10.1016/j.jaci.2010.07.019
4 Braman SS. The global burden of asthma. Chest. 2006;130:45-125. Medline:16840365 doi:10.1378/chest.130.1.suppl.45
5 van Gemert F, van der Molen T, Jones R, Chavannes N. The impact of asthma and COPD in sub-Saharan Africa. Prim Care Respir J. 2011;20:240-8. Medline:21509418 doi:10.4106/pcrj.2011.00027
6 Chan KY, Adelyoe D, Grant L, Kolčić I, Marušić A. How big is the ‘next big thing’? Estimating the burden of non-communicable diseases in low- and middle-income countries. J Glob Health. 2012;2:20101. Medline:23289068
7 Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24. Medline:19454036 doi:10.1186/1471-2466-9-24
8 Stanciolae AE, Ortegon M, Chisholm D, Lauer JA. Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e608. Medline:22389338 doi:10.1136/bmj.e608
9 ECRHS. European Community Respiratory Health Survey. Available from: http://www.ecrhss.org/. Accessed: December 20, 2013.
10 Cazzolleti L, Marcon A, Corsico A, Janson C, Jarvis D, Pin I, et al. Asthma severity according to Global Initiative for Asthma and its determinants: an international study. Int Arch Allergy Immunol. 2010;151:70-9. Medline:19672098 doi:10.1159/0002321272
11 Wong K, Rowe B, Douwes J, Senthilselvan A. International prevalence of asthma and wheeze in adults: Results from the world health survey. American Journal of Respiratory and Critical Care Medicine Conference: American Thoracic Society International Conference. ATS. 2010;181(1 MeetingAbstracts).
12 Dagoye D, Bekele Z, Voldemichael K, Nida H, Yinam M, Hall A, et al. Wheezing, allergy, and parasite infection in children in urban and rural Ethiopia. Am J Respir Crit Care Med. 2003;167:1369-73. Medline:12738598 doi:10.1164/rccm.200210-1204OC
13 Perzanowski MS, Ng’an’a LW, Carter MC, Odihambo J, Ngari P, Vaughan JW, et al. Atopy, asthma, and antibodies to Ascaris among rural and urban children in Kenya. J Pediatr. 2002;140:582-8. Medline:12032526 doi:10.1067/mpp.2002.122937
14 Wjst M, Boakye D. Asthma in Africa. PLoS Med. 2007;4:e72. Medline:17526712 doi:10.1371/journal.pmed.0040072
15 Patel SP, Jarvelin MR, Little MF. Systematic review of worldwide variations of the prevalence of wheezing symptoms in children. Environ Health. 2008;7:57. Medline:19000318 doi:10.1186/1476-069X-7-57
16 Martini P, Rosado-Pinto J, do Ceu Teixeira M, Neuparth N, Silva O, Tavares H, et al. Under-report and underdiagnosis of chronic respiratory diseases in an African country. Allergy. 2009;64:1061-7. Medline:19210360 doi:10.1111/j.1398-9995.2009.01956.x
17 Burney PG, Laitinen LA, Perdizet S, Hfuka H, Tattersfield AE, Chinn S, et al. Validity and repeatability of the IUATLD (1984) Bronchial Symptoms Questionnaire: an international comparison. Eur Respir J. 1989;2:940-5. Medline:2606194
18 Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469-78. Medline:15080825 doi:10.1111/j.1398-9995.2004.00526.x
19 Battikh MH, Ben Sayah MM, Jooobeur S, Naouar R, Maatallah A, Rouatbi N, et al. Clinical course of the ventilatory function in COPD: analytical study of 160 cases. Tunis Med. 2004;82:735-41. Medline:15532768
20 Ehrlich RI, Jordaan E, du Toit D, Volmink JA, Weinberg E, Zwarenstein M. Underrecognition and undertreatment of asthma in Cape Town primary school children. S Afr Med J. 1998;88:896-94. Medline:9754212
21 Wandalsen NF, Gonzalez C, Wandalsen GF, Sole D. Evaluation of criteria for the diagnosis of asthma using an epidemiological questionnaire. J Bras Pneumol. 2009;35:199-205. Medline:19390716 doi:10.1590/S1806-37132009000300002
22 Musafiri S, Joos G, Van Meerbeeck JP. Asthma, atopy and COPD in sub-Saharan countries: the challenges. East Afr J Public Health. 2011;8:161-3. Medline:22066305
23 Uijen AA, Schermer TRJ, van den Hoogen HMJ, Mulder J, Zantinge EM, Bottema BJAM. Prevalence of and health care consumption for...
an estimate of asthma prevalence in Africa: a systematic analysis

34 Benny S, Carlsen KCL, Hageberg R, Aandstad A, Mowinckel P, Andersen SA, et al. Asthma symptoms in rural living Tanzanian children: Prevalence and the relation to aerobic fitness and body fat. Allergy. 2009;64:1166-71. Medline:19210365 doi:10.1111/j.1398-9995.2009.01979.x

35 Bezzaucha A. Epidemiology of asthma in children and young adults in Algiers [in French]. Rev Mal Respir. 1992;9:417-23. Medline:1387241

36 Benarab-Boucherit Y, Mehdioui H, Nedjar F, Delpierre S, Bouchair N, Aberkan A. Prevalence rate of exercise-induced bronchoconstriction in Annaba (Algeria) schoolchildren. J Asthma. 2011;48:511-6. Medline:21548836 doi:10.3109/02770903.2011.578315

37 Desalu OO, Oluboyo PO, Salami AK. The prevalence of bronchial asthma among adults in Ilorin, Nigeria. Afr J Med Sci. 2009;38:149-54. Medline:20175418

38 Esamai F, Anabwani GM. Prevalence of asthma, allergic rhinitis and dermatitis in primary school children in Usain Gishu district, Kenya. East Afr Med J. 1996;73:474-8. Medline:8918014

39 Esamai F, Ayaya S, Nyandiko W. Prevalence of asthma, allergic rhinitis and dermatitis in primary school children in Usain Gishu district, Kenya. East Afr Med J. 2002;79:514-8. Medline:12635755 doi:10.4314/earmj.v79i10.8812

40 Addo-Yobo EOD, Woodcock A, Allotey A, Baffoe-Bonnie B, Strachan D, Custovic A. Exercise-induced bronchospasm and atopy in Ghana: two surveys ten years apart. PLoS Medicine. 2007;4:e70. Medline:17326711 doi:10.1371/journal.pmed.0040070

41 Ehrlich RI, Du Toit D, Jordaan E, Volmink JA, Weinberg EG, Zwarenstein M. Prevalence and reliability of asthma symptoms in primary school children in Cape Town. Int J Epidemiol. 1995;24:1138-45. Medline:8824855 doi:10.1093/ije/24.6.1138

42 Ehrlich RI, White N, Norman R, Laubscher R, Steyn K, Lombard C, et al. Wheeze, asthma diagnosis and medication use: a national adult survey in a developing country. Thorax. 2005;60:895-901. Medline:16263947 doi:10.1136/thx.2004.030932

43 Nafti S, Taricht S, Etloum M, Yassin N, Benkhedder A, Boucha H, et al. Prevalence of asthma in North Africa: the Asthma Insights and Reality in the Maghreb (AIRMAG) study. Respir Med. 2009;103 Suppl 2:252-11. Medline:20122625 doi:10.1016/S0954-6110(09)70022-8

44 Erhabor GE, Agboko SO, Bamigboye P, Awopenu OF. Prevalence of asthma symptoms among university students 15 to 35 years of age in Obafemi Awolowo University, Ille-Ife, Osun State. J Asthma. 2006;43:161-4. Medline:16517434 doi:10.1080/02770900500499046

45 Khalidi F, Fakhfakh R, Mattoussi N, Ben Ali B, Zouari S, Khemiri M. Prevalence and severity of asthma, allergic rhinoconjunctivitis and atopic eczema in “Grand Tunis” schoolchildren: ISAAC. Tunis Med. 2005;83:269-73. Medline:16044899

46 Koffi N, Yovo JC, Kouassi B, Ngom A, Toure M, Fadiga A, et al.
al. Prevalence of asthma in schoolchildren in 3 climatic regions of Cote d’Ivoire. Journal Medicine d’Afrique Noire. 2000;47:416-20.
48 Laraqui CH, Laraqui O, Rahhal A, Harouart K, Tripodi D, Mounassif M, et al. Prevalence of respiratory problems in workers at two manufacturing centers of ready-made concrete in Morocco [in French]. Int J Tuberc Lung Dis. 2001;5:1051-8. Medline:11718134
49 Mavale-Manuel S, Joaquim O, Nunes E, Pedro A, Bandeira S, Eduardo E, et al. Prevalence of asthma-like symptoms by ISAAC video questionnaire in Mozambican schoolchildren. Monaldi Arch Chest Dis. 2006;65:189-95. Medline:17393663
50 Falade AG, Olawuyi JF, Odunsi K, Onadeko BO. Prevalence and severity of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema in 6- to 7-year-old Nigerian primary school children: the international study of asthma and allergies in childhood. Med Princ Pract. 2004;13:20-5. Medline:14657614 doi:10.1159/000074046
51 Faniran AO, Peat JK, Woolcock AJ. Prevalence of atopy, asthma symptoms and diagnosis, and the management of asthma: Comparison of an affluent and a non-affluent country. Thorax. 1999;54:606-10. Medline:10377205 doi:10.1136/thx.54.7.606
52 Georgy V, Fahim HI, El-Gaafary M, Walters S. Prevalence and socioeconomic associations of asthma and allergic rhinitis in northern Africa. Eur Respir J. 2006;28:756-62. Medline:16737986 doi:10.1183/09031936.06.00089005
53 Hailu S, Tessema T, Silverman M. Prevalence of symptoms of asthma and allergies in schoolchildren in Gondar town and its vicinity, Northwest Ethiopia. Pediatr Pulmonol. 2003;35:427-32. Medline:12746938 doi:10.1002/ppul.10215
54 Mashalane MBN, Stewart A, Feldman C, Becker P, de Charmoy A. Prevalence of exercise-induced bronchospasm in Thokoza schoolchildren. S Afr Med J. 2006;96:67-70. Medline:16440116
55 Miningou SD, Zoubga AZ, Medina H, Medina N, Tiendrebeogo H. Prevalence of asthma in subjects aged 15-64 years in Bobo-Dioulasso (Burkina Faso) in 1998 [in French]. Rev Pneumol Clin. 2002;58:341-5. Medline:12545132
56 Miszukurma M, Hadiad S, Langois EV, Freeman EE, Kouanda S, Zununegui MV. Heavy burden of non-communicable diseases at early age and gender disparities in an adult population of Burkina Faso: World Health Survey. BMC Public Health. 2012;12:24. Medline:22233590 doi:10.1186/1471-2458-12-24
57 Musafiri S, van Meerbeek J, Musango L, Brusselle G, Joos G, Seminega B, et al. Prevalence of atopy, asthma and COPD in an urban and a rural area of an African country. Respir Med. 2011;105:1596-605. Medline:21783353 doi:10.1016/j. rmed.2011.06.013
58 Mustapha BA, Blangiardo M, Briggs DJ, Hansell AL. Traffic air pollution and other risk factors for respiratory illness in schoolchildren in the niger-delta region of Nigeria. Environ Health Perspect. 2011;119:1478-82. Medline:21719372 doi:10.1289/ehp.1003099
59 Ng’ang’a LW, Odhiambo JA, Mungai MW, Gicheha CM, Nderitu P, Maingi B, et al. Prevalence of exercise induced bronchospasm in Kenyan school children: An urban-rural comparison. Thorax. 1998;53:919-26. Medline:10019388 doi:10.1136/thx.53.11.919
60 Nriagu J, Robins T, Gary L, Liggans G, Davila R, Supuwook K, et al. Prevalence of asthma and respiratory symptoms in south-central Durban, South Africa. Eur J Epidemiol. 1999;15:747-55. Medline:10555619 doi:10.1023/A:1007653709188
61 Nyembue TD, Jorissen M, Hellings PW, Muyunga C, Kayembe JM. Prevalence and determinants of allergic diseases in a Congolese population. International Forum of Allergy and Rhinology. 2012;2:285-93.
62 Poyer MA, Nelson H, Ehrlich RL, Bateman ED, Parnell S, Puterman A, et al. Socioeconomic deprivation and asthma prevalence and severity in young adolescents. Eur Respir J. 2002;19:492-8. Medline:12030730 doi:10.1183/09031936.02.00238402
63 Roudaut M, Medina AH, Seka A, Fadiga D, Pigraus B, Akoto A. Prevalence of asthma and respiratory diseases in schools in Bouake (Ivory Coast): preliminary results [in French]. Med Trop (Mars). 1992;52:279-83. Medline:1331695
64 Sallaoui R, Chamari K, Cheta M, Alaranta A, Manai Y, Ghedira H, et al. Asthma in Tunisian elite athletes. Int J Sports Med. 2007;28:571-5. Medline:17436195 doi:10.1055/s-2007-964838
65 Terblanche E, Stewart RI. The prevalence of exercise-induced broncho-constriction in Cape Town schoolchildren. S Afr Med J. 1990;78:744-7. Medline:2251634
66 Wolff PT, Arison L, Rahajamiakatra A, Raserijaona F, Niggemann B. High asthma prevalence and associated factors in urban malagasy schoolchildren. J Asthma. 2012;49:575-80. Medline:22793524 doi:10.1177/02770903.2012.696170
67 Mtshali BF, Mokwena KE. The prevalence of exercise-induced broncho-constriction among school children. S Afr Fam Pract. 2009;51:489-91.
68 Odhiambo JA, Ng’ang’a LW, Mungai MW, Gicheha CM, Nyamwuya JK, Karimi F, et al. Urban-rural differences in questionnaire-derived markers of asthma in Kenyan school children. Eur Respir J. 1998;12:1105-12. Medline:9864005 doi:10.1183/09031936.98.12051105
69 Walraven GE, Nyan OA, Van Der Sande MA, Banya WA, Ceesay SM, Milligan PJ, et al. Asthma, smoking and chronic cough in rural and urban adult communities in The Gambia. Clin Exp Allergy. 2001;31:1679-85. Medline:11696043 doi:10.1046/j.1365-2222.2001.01094.x
70 Wichmann J, Wolvaardt JE, Maritz C, Voyi KKV. Household conditions, eczema symptoms and rhinitis symptoms: relationship with wheeze and severe wheeze in children living in the Polokwane area, South Africa. Matern Child Health J. 2009;13:107-18. Medline:18185988 doi:10.1007/s10995-007-0309-x
71 Yemaneberhan H, Bekele Z, Venn A, Lewis S, Parry E, Britton J. Prevalence of wheeze and asthma and relation to atopy in urban and rural Ethiopia. Lancet. 1997;350:85-90. Medline:9228959
Adeloye et al: An estimate of asthma prevalence in Africa: a systematic analysis

www.cmj.hr

doi:10.1016/S0140-6736(97)01151-3

72 Morais de Almeida M, Gaspar A, Rosado Pinto J. Epidemiology of asthma in Portugal, Cape Verde, and Macao. Pediatr Pulmonol. 2001;3(Suppl):35-7. Medline:11886140

73 Mengesha YA, Bekele A. Relative chronic effects of different occupational dusts on respiratory indices and health of workers in three Ethiopian factories. Am J Ind Med. 1998;34:373-80. Medline:9750944 doi:10.1002/(SICI)1097-0274(199810)34:4<373::AID-AJM11>3.0.CO;2-8

74 Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996.

75 Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-223. Medline:23245608 doi:10.1016/S0140-6736(12)61689-4

76 Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128. Medline:23245604 doi:10.1016/S0140-6736(12)61728-0

77 Fan V, Lam F. Malaria estimate sausages by WHO and IHME. Washington DC, USA: Centre for Global Development; 2012; Available from: http://www.cgdev.org/blog/malaria-estimate-sausages-who-and-ihme. Accessed: December 22, 2013.

78 Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Degenhardt L. How did we arrive at burden of disease estimates for mental and illicit drug use disorders in the Global Burden of Disease Study 2010? Curr Opin Psychiatry. 2013;26:376-83. Medline:23689547 doi:10.1097/YCO.0b013e328361e60f

79 Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370:741-50. Medline:17765523 doi:10.1016/S0140-6736(07)61377-4

80 Hnizdo E, Esterhuizen TM, Rees D, Laloo UG. Occupational asthma as identified by the Surveillance of Work-related and Occupational Respiratory Diseases programme in South Africa. Clin Exp Allergy. 2001;31:32-9. Medline:11167948 doi:10.1046/j.1365-2222.2001.00981.x

81 Aït-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ. 2001;79:971-9. Medline:11693980

82 Ben Abdallah F, Taktak S, Chouourou A, Mahouachi R, Ben Kheder A. Burden of chronic respiratory diseases (CRD) in middle east and North Africa (MENA). World Allergy Organization Journal. 2011;4 SUPPL. 1:56-6. Medline:23283069

83 Bahadori K, Quon BS, Doyle-Waters MM, Manra C, Fitzgerald JM. A systematic review of economic evaluations of therapy in asthma. J Asthma Allergy. 2010;3:33-42. Medline:21437038 doi:10.2147/JAA.511038

84 Mackay D, Haw S, Ayres JG, Fischbacher C, Pell JF. Smoke-free legislation and hospitalizations for childhood asthma. N Engl J Med. 2010;363:1139-45. Medline:20843248 doi:10.1056/NEJMoa1002861

85 Jindal SK, Aggarwal AN, Chaudhry K, Chhabra SK, D’Souza GA, Gupta D, et al. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. Indian J Chest Dis Allied Sci. 2006;48:23-9. Medline:16482948

86 Salama AA, Mohammed AA, El Okda ESE, Said RM. Quality of care of Egyptian asthmatic children: clinicians adherence to asthma guidelines. Italian Journal of Pediatrics. 2010;36:33.

87 Asthma WHO. (Fact sheets). Geneva, Switzerland: World Health Organization; 2012. Available from: http://www.who.int/mediacentre/factsheets/fs307/en/index.html. Accessed: December 22, 2013.

88 Zaraket R, Al-Tannir MA, Bin Abdulhak AA, Shatila A, Lababidi H. Parental perceptions and beliefs about childhood asthma: a cross-sectional study. Croat Med J. 2011;52:637-43. Medline:21990082 doi:10.3325/cmj.2011.52.637
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Adeloye, D; Chan, KY; Rudan, I; Campbell, H

Title:
An estimate of asthma prevalence in Africa: a systematic analysis

Date:
2013-12-01

Citation:
Adeloye, D., Chan, K. Y., Rudan, I. & Campbell, H. (2013). An estimate of asthma prevalence in Africa: a systematic analysis. CROATIAN MEDICAL JOURNAL, 54 (6), pp.519-531. https://doi.org/10.3325/cmj.2013.54.519.

Persistent Link:
http://hdl.handle.net/11343/259605

File Description:
Published version

License:
CC BY